Effect of CML drugs on blood sugar and cholesterol
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how certain CML treatments called tyrosine kinase inhibitors affect blood sugar and cholesterol levels in people with chronic myeloid leukemia. It may help understand if these drugs change metabolism.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic myeloid leukemia (CML).
- You do not have diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your current leukemia medicines and herbal or plant-based products may interact, and how that could affect outcomes in chronic myeloid leukemia. It may help doctors better understand which drug combinations are safest and most effective.
This study looks at how a person's personality might affect how well they take their CML medication. It's for people with chronic phase CML who are taking certain targeted therapy pills (imatinib, dasatinib, bosutinib, or nilotinib).
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This trial looks at how a targeted therapy called TKI (tyrosine kinase inhibitor) affects thyroid function in patients newly diagnosed with chronic myeloid leukemia (CML). It aims to understand any changes in the thyroid gland during treatment.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.